QuidelOrtho Corp (QDEL): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$442.00M
Year ended 2025-12-28
$454.20M
Trailing 12 months to 2026-06-28
+15.9%
3-year compound annual growth
+55.4%
5-year compound annual growth
$457.20M2021-01-03: $48.80M2022-01-02: $52.70M2023-01-01: $283.60M2023-12-31: $457.20M2024-12-29: $453.40M2025-12-28: $442.00M$442.00M
2021-01-03 Depreciation & Amortization (USD) 2025-12-28
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-28$442.00M-2.5%2026-02-19, From 2024-12-30
2024-12-29$453.40M-0.8%2026-02-19, From 2024-01-01
2023-12-31$457.20M+61.2%2026-02-19, From 2023-01-02
2023-01-01, Fiscal 2022$283.60M+438.1%2025-02-27, From 2022-01-03
2022-01-02, Fiscal 2021$52.70M+8.0%2024-08-01, From 2021-01-04
2021-01-03, Fiscal 2020$48.80Mn/a2023-02-23, From 2019-12-30

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
QuidelOrtho Corp (QDEL)2025-12-28$442.00M-2.5%
Idexx Laboratories Inc (IDXX)2025-12-31$145.18M+11.7%
Lantheus Holdings, Inc. (LNTH)2025-12-31$70.10M+8.5%
Neogen Corp (NEOG)2026-05-31$116.30M-2.7%
Myriad Genetics Inc (MYGN)2025-12-31$53.70M-12.3%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$9.77M-5.0%
Alpha Teknova, Inc. (TKNO)2025-12-31$6.34M-3.6%
Immucell Corp (ICCC)2025-12-31$2.78M+2.0%
Aspira Women's Health Inc. (AWHL)2025-12-31$112.0K+21.7%

Compare QDEL, IDXX, LNTH, NEOG side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗